Health5 hours ago
Intellia Therapeutics Shares Surge After Angioedema Study Enrollment Completion
Intellia Therapeutics has announced the completion of participant enrollment in its late-stage study of the drug lonvoguran ziclumeran, aimed at treating hereditary angioedema. Following this news,...